GlassScriptPhysician profile
Michael Sandridge
NPI 1396296836
$8,523.43
in general payments reported to CMS, 2019-2025
29 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,268 · 2022: $1,780 · 2023: $1,866 · 2024: $2,248 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,464 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,464.20 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,236.66 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $704.74 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $639.91 | 2021-2025 | Trintellix |
| Lundbeck LLC | $574.70 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $349.69 | 2022-2025 | Austedo, Uzedy, Austedo Xr |
| Almatica Pharma LLC | $349.62 | 2021-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $348.34 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $347.49 | 2021-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $306.05 | 2023-2024 | Dyanavel Xr |
| Corium, LLC | $277.63 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $247.51 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $206.64 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $202.84 | 2022-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $201.51 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $172.17 | 2021-2024 | Ingrezza |
| Bausch Health US, LLC | $171.14 | 2022-2024 | Aplenzin |
| Harmony Biosciences LLC | $92.18 | 2022-2023 | Wakix |
| Neos Therapeutics, LP | $83.86 | 2022-2025 | Adzenys Xr-Odt |
| Avadel Cns Pharmaceuticals, LLC | $70.56 | 2024-2025 | Lumryz |
| Avanir Pharmaceuticals, INC. | $70.06 | 2021-2022 | |
| Eisai INC. | $38.18 | 2021 | |
| Sunovion Pharmaceuticals INC. | $36.97 | 2021 | |
| Collegium Pharmaceutical, INC. | $29.42 | 2025 | Jornay Pm |
| Tonix Medicines, INC. | $23.19 | 2025 | Tonmya |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.65 | 2023 | |
| Ironshore Pharmaceuticals INC. | $19.03 | 2023 | Jornay Pm |
| Alfasigma USA, INC. | $15.29 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.15 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sandridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.